Replies to post #221805 on Biotech Values

[willyw]

I am interested but hold no expertise, whatsoever.

The RSV conference was structured like a liver conference; areas of interest, poster sections and presentations.
A few weeks ago it looked as though the main oral presentations were to be JNJ and Enta; then JNJ back burnered their RSV program

One can check Clinical trials
https://clinicaltrials.gov/ct2/results?cond=RSV+Infection&term=&cntry=&state=&city=&dist=

and

One can check the RSV conference
https://www.isirv.org/site/images/conferences/RSV/RSV2018%20Program%2025%20October.docx.pdf

It looks to me like the two areas of attack would be vaccines
and experimental agents. It looked like the oral presentation of experimental agents were JNJ and ENTA.
There is a detailed list with 6 pages of abstracts
https://www.isirv.org/site/images/conferences/RSV/Posters_Poster%20number%20order.pdf

To me... it doesn't look like a crowded field